About
Dr. Alon Lazarus joined Arkin Bio in 2013 as a Managing Partner, where he led investments in pharmaceutical companies from early stages through U.S. public offerings and served on several portfolio company boards. Earlier in his career, he worked in the healthcare business development department of Yissum, the R&D arm of the Hebrew University of Jerusalem.
Invests in
BiotechHealthtech
Experience
- Arkin HoldingsBiotech Analyst2013 — 2024
- Yissumbusiness development - Healthcare2012 — 2013
- Integra HoldingsAnalyst2012 — 2013
Education
- Hebrew University-Hadassah Medical School, Jerusalem, Israel,Doctor of Philosophy (Ph.D.), Molecular Biology2005 — 2011
- Hebrew University, School of Business Administration, Jerusalem, IsraelMaster of Business Administration (MBA), Specialization in Finance and Banking2007 — 2009
- Hebrew University, Faculty of Science, Jerusalem, IsraelBachelor of Science (B.Sc.), Biology2000 — 2003
Shared employers
Investments
Board seats
Auron TherapeuticsBluejay TherapeuticsEnact BioHI-BioModal TherapeuticsWerewolf Therapeutics
Per the firm's website.
Colleagues at Arkin Capital
Adar Makovski Silverstein
Principal at Arkin Capital
Avital Adler
Principal at Arkin Capital
Benzion Amoyav
Investment Analyst at Arkin Capital
Chen Koton
Direct Equity at Arkin Capital
Dana Azulay
Bookkeeper at Arkin Capital
Danny Kleinhendler
Legal Counsel at Arkin Capital
David Alterman
Principal at Arkin Capital
Einav Sheffi-Malbin
Bookkeeper at Arkin Capital